| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.05T | 2.07T | 2.02T | 2.04T | 1.70T | 1.41T |
| Gross Profit | 494.73B | 499.05B | 481.36B | 529.38B | 513.00B | 359.06B |
| EBITDA | 270.91B | 146.12B | 315.38B | 252.23B | 381.25B | 209.33B |
| Net Income | 34.36B | -94.04B | 65.80B | -3.15B | 123.84B | 32.72B |
Balance Sheet | ||||||
| Total Assets | 2.80T | 2.89T | 2.93T | 2.81T | 2.67T | 2.53T |
| Cash, Cash Equivalents and Short-Term Investments | 100.49B | 107.99B | 146.06B | 209.72B | 195.83B | 236.12B |
| Total Debt | 650.79B | 649.74B | 695.01B | 650.24B | 603.19B | 787.96B |
| Total Liabilities | 1.20T | 1.22T | 1.28T | 1.23T | 1.18T | 1.29T |
| Stockholders Equity | 1.38T | 1.44T | 1.45T | 1.39T | 1.31T | 1.12T |
Cash Flow | ||||||
| Free Cash Flow | 41.16B | 42.46B | -985.00M | -6.78B | 116.14B | 33.92B |
| Operating Cash Flow | 259.73B | 284.81B | 212.55B | 217.15B | 326.71B | 225.39B |
| Investing Cash Flow | -204.69B | -195.58B | -179.79B | -145.31B | -123.79B | -230.25B |
| Financing Cash Flow | -58.87B | -131.95B | -108.02B | -78.21B | -252.26B | 128.44B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $357.65B | 8.50 | 11.71% | 4.52% | 1.29% | -22.20% | |
| ― | $555.40B | 13.32 | 6.42% | 3.49% | -6.27% | 40.98% | |
| ― | $265.98B | 11.74 | 4.90% | 3.52% | 3.80% | -11.14% | |
| ― | ¥646.31B | 18.88 | 12.59% | 1.63% | 4.89% | -3.79% | |
| ― | $1.02T | 29.60 | 2.45% | 4.36% | -0.06% | ― | |
| ― | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
| ― | $693.99B | 45.84 | 1.78% | 4.11% | -0.91% | -74.07% |
AGC Inc., a prominent player in the glass and chemicals industry, operates globally across various sectors including architectural glass, automotive, electronics, chemicals, and life sciences.
AGC Inc. has revised its financial forecasts for the fiscal year ending December 31, 2025, citing a decrease in net sales and operating profit due to production issues in its biopharmaceuticals CDMO business, lower PVC sales prices, and reduced sales volume of semiconductor-related products. The company also anticipates lower profits due to impairment losses from structural reforms at its Boulder and Longmont sites in Colorado, USA. Despite these challenges, the dividends forecast remains unchanged.
The most recent analyst rating on (JP:5201) stock is a Hold with a Yen4700.00 price target. To see the full list of analyst forecasts on AGC stock, see the JP:5201 Stock Forecast page.
AGC Inc. reported a decrease in net sales and operating profit for the first half of 2025 compared to the previous year, with net sales at 995,474 million yen and operating profit at 54,022 million yen. Despite these declines, the company turned a profit before tax of 33,751 million yen, a significant improvement from the loss reported in the same period last year. The company’s financial forecast for the full year 2025 anticipates a slight decrease in net sales and operating profit, but an overall profit for the period. This indicates a potential recovery and stabilization in AGC’s financial performance, which could positively impact stakeholders and improve its position in the market.
The most recent analyst rating on (JP:5201) stock is a Hold with a Yen5000.00 price target. To see the full list of analyst forecasts on AGC stock, see the JP:5201 Stock Forecast page.